Endo International PLC at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us. I am Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. And our next company presenting today is Endo International. I'm joined this morning by Blaise Coleman, President and CEO; and Pat Barry, EVP and President of Global Commercial Operations.
Blaise, there's a lot to cover across your branded, specialty injectable, and generic businesses, including the recent launch of Qwo, which I certainly have some questions on, but I'd like to start with a more high-level question.
A lot has changed in the US over the past few months as more people have been vaccinated and the economy continues to reopen. Can you talk about how the pandemic has affected your business to date and how you expect the reopening process to influence the Company over the remainder of 2021?
Sure. Well first off, Dan, it's great to be here with you. Good morning to everybody listening. We really appreciate those joining
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |